Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.

VUMC is playing a key role in a national effort to establish a registry of U.S. health care workers and test whether the anti-malarial drug hydroxychloroquine (HCQ) will protect them, their patients and their families from COVID-19.

Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.

Danny Winder and colleagues are teasing apart the actions of neurotransmitter receptors in a brain region linked to anxiety and addiction, with a goal of finding treatments for substance use disorders.

Last week, France’s health ministry urged people who have been infected by the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) to avoid taking over-the- counter nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen and aspirin because they might increase the severity of the infection.

Jennifer Doudna, PhD, who led development of the revolutionary genome editing technology known as CRISPR-Cas9, is the recipient of the 2020 Vanderbilt Prize in Biomedical Science, officials at Vanderbilt University Medical Center announced this week.